| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 300436 | 广生堂 | 1 | 20.00 | 153亿 | 8.00 | | 301093 | 中三股份 | 资 | 12.00 | 138亿 | 63.89 | | 600774 | 汉商集团 * | | 10.00 | 34.08亿 | 26.37 | | 300683 | 海特生物 | 资 | 7.92 | 43.71亿 | 20.41 | | 688759 | 必贝特-U | 1 | 6.64 | 249亿 | 90.09 | | 300204 | 舒泰神 | 1 | 5.78 | 136亿 | 4.58 | | 688222 | 成都先导 | 中 | 5.42 | 138亿 | 46.78 | | 000078 | 海王生物 | 1 | 5.23 | 101亿 | 10.40 | | 600998 | 九州通 | 1 | 4.71 | 280亿 | 8.59 | | 301230 | 泓博医药 | | 4.60 | 67.60亿 | 62 ...

1月23日，A股市场医药商业股集体上涨，其中，人民同泰、益丰药房涨停，鹭燕医药涨超7%，大参林涨超6%， 九州通涨超5%，重药控股、药易购、海王生物、合富中国、漱玉平民涨超4%。 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 消息面上，商务部等9部门发文提出：完善药事服务，提升药学服务能力，促进处方流转提升购药体验，优化定点 零售药店门诊统筹服务，推动药品零售企业参加药品集中采购等措施。鼓励药品零售企业依法开展横向并购与重 组。鼓励创新药、参比制剂等药品进零售药店销售渠道。鼓励医药电商平台开放数据接口，加强线上、线下药品 零售价与省级医药采购平台挂网价的联动监测，加强定点药店医保药品量价比较指数和药品比价小程序的推广应 用。 | 代码 | 名称 | 0 | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | | --- | --- | --- | --- | --- | --- | --- | | 600829 | 人民同泰 | 事 | 10.04 | 72.43亿 | 15.54 | 12.49 | | 603939 | 益丰药房 | 1 | 10.02 | 301亿 | 14.23 | 2 ...

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]

证券代码：000078 证券简称：海王生物 公告编号：2026-005 深圳市海王生物工程股份有限公司 关于对外担保进展暨解除对外担保的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特此公告。 深圳市海王生物工程股份有限公司 董 事 局 具体内容详见公司在《证券时报》《上海证券报》《中国证券报》《证券日 报》及巨潮资讯网上披露的相关公告。 二、担保进展情况 截至目前，公司对六安海王的担保义务均已完全解除，公司对其债务均已不 存在任何形式的担保。 三、其他说明 截至目前，本公司累计担保余额约为人民币44.31亿元（均为对子公司担保）， 约占公司2024年度经审计合并报表净资产的比例为155.81%，不存在逾期担保的 情况。 一、担保情况概述 深圳市海王生物工程股份有限公司（以下简称"公司"或"本公司"）于2025年 12月29日召开的第十届董事局第五次会议及2026年1月16日召开的2026年第一次 临时股东会审议通过了《关于担保延续构成对外担保的议案》。 公司控股子公司安徽海王医药集团有限公司与六安海王医药有限公司（以下 简称"六安海王"）的小股东安徽 ...

Market Overview - On January 16, the A-share market opened high but closed lower, with the Shanghai Composite Index down 0.26% at 4101.91 points, and both the Shenzhen Component and ChiNext Index down 0.18% and 0.20% respectively. The total trading volume exceeded 2 trillion yuan for the 14th consecutive trading day, reaching 3.03 trillion yuan [1]. Sector Performance - The market focus was on the semiconductor industry chain, particularly in storage chips and silicon carbide, as well as power grid equipment and humanoid robots. The low-altitude economy concept saw a recovery in the afternoon, while AI applications and sectors like media and pharmaceuticals experienced significant adjustments [1]. - A total of 2371 stocks rose while 2973 fell, with 47 stocks hitting the daily limit up and 50 hitting the limit down, indicating a low short-term sentiment and a less than 30% success rate for consecutive limit-up stocks [1]. Fund Flow - Main funds saw a net inflow of over 22.2 billion yuan into the electronics sector, with significant investments in semiconductors and machinery equipment, while there was a large outflow from the computer and media sectors, amounting to 18.56 billion yuan and 10.64 billion yuan respectively [1]. - Northbound funds recorded a net purchase of about 5 billion yuan, focusing on technology consumer stocks like Luxshare Precision and Sanhua Intelligent Control [1]. Market Sentiment - The market maintained high trading volume but with slowing incremental growth. The surge in wide-based ETFs indicated a risk-averse tendency, as funds sought a balance between policy catalysts and performance certainty in sectors like consumer electronics and innovative pharmaceuticals [1]. - The overall market saw a 40% limit-down rate, with the number of stocks hitting the limit down (50) exceeding those hitting the limit up (47), reflecting increased fund divergence and a decline in risk appetite [1]. First Limit Down Stocks - Haiwang Bio (000078) faced a limit down due to high valuation and fund withdrawal, closing at 3.74 yuan with a drop of 10.10%, and showing a significant deviation of 86.04% from its intrinsic value [2][3]. - Sanwei Communication (002115) also hit a limit down as high valuation pressures emerged, closing at 17.59 yuan with a drop of 9.98%, and a deviation of 67.83% from its intrinsic value [4][5]. - Hezhu Intelligent (603011) experienced a limit down due to overall sector adjustments, closing at 28.81 yuan with a drop of 9.99%, and a deviation of 60.08% from its intrinsic value [6][7]. Continuous Limit Down Stocks - Jinyu Group (601992) saw a continuous limit down, closing at 1.9 yuan with a drop of 9.95%, and is currently undervalued by 80.69% compared to its intrinsic value, indicating potential for valuation recovery [9][10]. - Hangxiao Steel Structure (600477) also faced a continuous limit down, closing at 3.61 yuan with a drop of 9.98%, and is undervalued by 51.59% compared to its intrinsic value, suggesting a potential investment opportunity [11][12]. - Zhejiang Wenlian (600986) experienced a continuous limit down, closing at 10.04 yuan with a drop of 9.96%, and is undervalued by 36.81% compared to its intrinsic value, indicating potential for valuation recovery as market sentiment stabilizes [13][14]. Investment Strategy - The market is showing a tendency to avoid significantly overvalued stocks, focusing instead on undervalued stocks with fundamental support. Investors are advised to avoid first limit down stocks like Haiwang Bio and Sanwei Communication, while considering opportunities in continuously limit down stocks like Jinyu Group and Hangxiao Steel Structure [15][16].

Core Viewpoint - The announcement details the resolutions passed during the first extraordinary general meeting of shareholders for Shenzhen Haiwang Biological Engineering Co., Ltd. in 2026, confirming the legality and validity of the meeting and its decisions [1][5][13]. Meeting Details - The meeting was held on January 16, 2026, at 14:50, with both on-site and online voting options available [3][4]. - The location of the meeting was at the 24th floor of Haiwang Galaxy Technology Building, Nanshan District, Shenzhen [4]. - The meeting was chaired by Mr. Zhang Feng, the chairman and president of the board [5]. Attendance - A total of 1,404 shareholders attended the meeting, representing 1,242,292,136 shares, which is 47.2153% of the total voting shares [6]. - Among these, 4 shareholders attended in person, representing 1,219,283,921 shares (46.3408%), while 1,400 shareholders participated via online voting, representing 23,008,215 shares (0.8745%) [6][7]. - A total of 1,402 minority shareholders participated, representing 24,515,915 shares (0.9318%) [8]. Resolutions Passed - The first resolution regarding the transfer of equity in a controlling subsidiary, which resulted in external financial assistance, was approved with 99.4052% of the votes in favor [10]. - The second resolution concerning the continuation of guarantees constituting external guarantees was also approved, with 99.3765% of the votes in favor [11]. Legal Verification - The meeting was witnessed by lawyers from Beijing Deheng (Shenzhen) Law Firm, who confirmed that the meeting's procedures and resolutions complied with relevant laws and regulations [12][13].

Group 1 - The company, Haiwang Biological, announced the approval of two significant proposals during its first extraordinary shareholders' meeting of 2026 [2] - The first proposal involves the transfer of equity in a controlling subsidiary, which has resulted in passive external financial assistance [2] - The second proposal pertains to the continuation of guarantees that constitute external guarantees [2]

证券代码：000078 证券简称：海王生物 公告编号：2026-004 深圳市海王生物工程股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、重要提示 本次会议召开期间无增加、否决或变更提案的情况。 二、会议召开情况 （一）会议召开时间 （1）现场会议：2026年1月16日（星期五）下午14:50 （2）网络投票：2026年1月16日（星期五）。其中，通过深圳证券交易所交 易系统进行网络投票时间为2026年1月16日（星期五）上午9:15-9:25，9:30-11:30 和下午13:00-15:00；通过深圳证券交易所互联网投票系统投票时间为2026年1月 16日（星期五）9:15-15:00的任意时间。 （二）现场会议召开地点 深圳市南山区科技园科技中三路 1 号海王银河科技大厦 24 楼会议室 （三）会议召集人 深圳市海王生物工程股份有限公司董事局 （四）投票方式 本次会议由公司董事局主席、总裁张锋先生主持召开。 （六）本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股 东会规则》等有关法律、行 ...

北京德恒（深圳）律师事务所 关于深圳市海王生物工程股份有限公司 2026 年第一次临时股东会的 法律意见 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话：0755-88286488 传真：0755-88286499 邮编：518026 北京德恒（深圳）律师事务所关于深圳市海王生物工程股份有限公司 2026 年第一次临时股东会的法律意见 北京德恒（深圳）律师事务所 关于深圳市海王生物工程股份有限公司 2026 年第一次临时股东会的 法律意见 致：深圳市海王生物工程股份有限公司 深圳市海王生物工程股份有限公司（以下简称"公司"）2026 年第一次临 时股东会（以下简称"本次会议"）于 2026 年 1 月 16 日（星期五）召开。北京 德恒（深圳）律师事务所（以下简称"德恒"）受公司委托，指派曹中海律师、 徐梦丹律师（以下简称"德恒律师"）出席了本次会议。根据《中华人民共和国 证券法》（以下简称"《证券法》"）《中华人民共和国公司法》（以下简称"《公 司法》"）中国证券监督管理委员会《上市公司股东会规则》（以下简称"《股 东会规则》"）《深圳市海王生物工程股份有限公司章程》（以下简称"《公司 章 ...

从资金流向上来看，当日医药商业板块主力资金净流出9.72亿元，游资资金净流入7722.04万元，散户资 金净流入8.95亿元。医药商业板块个股资金流向见下表： 证券之星消息，1月16日医药商业板块较上一交易日下跌2.34%，海王生物领跌。当日上证指数报收于 4101.91，下跌0.26%。深证成指报收于14281.08，下跌0.18%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 000411 | 英特集团 | 13.76 | 2.30% | 28.54万 | | 3.91亿 | | 600538 | 国发股份 | 6.43 | 1.74% | 20.75万 | | 1.32亿 | | 603233 | 大参林 | 19.00 | 1.33% | 6.82万 | | 1.29亿 | | 301584 | 建发致新 | 31.66 | 0.60% | 5.15万 | | 1.63亿 | | 600833 | 第一医药 | 13.28 | -0.15% ...